Mouse V-Set And Immunoglobulin Domain-Containing Protein 4 (VSIG4) Protein
273€ (10 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Mouse V-Set And Immunoglobulin Domain-Containing Protein 4 (VSIG4) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx690774
tested applications
SDS-PAGE
Description
V-Set And Immunoglobulin Domain-Containing Protein 4 (VSIG4) protein is a recombinant protein expressed in HEK293 cells.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | V-Set And Immunoglobulin Domain-Containing Protein 4 (VSIG4) |
| Host | HEK293 cells |
| Assay Type | Activity: Not tested Sequence Fragment: His20-Pro187 Tag: C-terminal 6 His tag |
| Origin | Mouse |
| Observed MW | Calculated MW: 19.7 kDa Observed MW (SDS-PAGE): 28-35 kDa |
| Expression | Recombinant |
| Purity | > 95% (SDS-PAGE) |
| Purification | 0.2 µm filtered prior to lyophilization. |
| Size 1 | 10 µg |
| Size 2 | 50 µg |
| Form | Lyophilized |
| Tested Applications | SDS-PAGE |
| Buffer | Prior to lyophilization: PBS, pH 7.4, containing 5%-8% Trehalose, Mannitol and 0.01% Tween 80. |
| Availability | Shipped within 5-15 working days. |
| Storage | Storage: Store lyophilized between -20 °C and -80°C. Stability: Stable when stored reconstituted at 2-8°C for up to 1 week. Reconstituted aliquots are stable at -20°C for up to 3 months. Shelf Life: 12 months. |
| Dry Ice | No |
| Alias | CRIg,Z39IG,Protein Z39Ig |
| Background | Protein VSIG4 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. Reconstitute in sterile H2O to prepare a stock solution of concentration 0.25 mg/ml. Do not vortex. Endotoxin Level: < 1.0 EU per µg (LAL method). |
Descripción
V-set and immunoglobulin domain containing 4 (VSIG4) is a complement receptor and immune checkpoint protein that primarily functions as an inhibitory molecule in macrophages and antigen-presenting cells. As a negative regulator of T-cell activation, VSIG4 suppresses immune responses by binding to complement components, thereby reducing inflammation and preventing tissue damage in autoimmune and inflammatory conditions. Its immune-inhibitory properties make VSIG4 a potential target for immune modulation therapies, particularly in autoimmune diseases and cancer immunotherapy. In the tumor microenvironment, VSIG4 expression on macrophages is associated with immune evasion, as it inhibits T-cell-mediated anti-tumor responses. Elevated VSIG4 levels have been linked to poor prognosis in several cancers, including hepatocellular carcinoma and melanoma. Beyond its role in immunity, VSIG4 is implicated in metabolic processes, as it interacts with lipid metabolism pathways in macrophages, influencing foam cell formation in atherosclerosis. Therapeutic strategies targeting VSIG4 are being explored to enhance anti-tumor immunity or regulate excessive inflammation, highlighting its significance as a multifunctional immune regulatory molecule.
